Architecture of deep neural networks. by Ahmed Muqdad Alnasrallah (21647492)

“…The proposed model employs Information Gain (IG) and Recursive Feature Elimination (RFE) in parallel to select the top 50% of features, from which intersection and union subsets are created, followed by a deep autoencoder (DAE) to reduce dimensionality without losing important data. …”

Proposed model framework. by Ahmed Muqdad Alnasrallah (21647492)

“…The proposed model employs Information Gain (IG) and Recursive Feature Elimination (RFE) in parallel to select the top 50% of features, from which intersection and union subsets are created, followed by a deep autoencoder (DAE) to reduce dimensionality without losing important data. …”

WUSTL-EHMS-2020 dataset information. by Ahmed Muqdad Alnasrallah (21647492)

“…The proposed model employs Information Gain (IG) and Recursive Feature Elimination (RFE) in parallel to select the top 50% of features, from which intersection and union subsets are created, followed by a deep autoencoder (DAE) to reduce dimensionality without losing important data. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Impact of Fixed Nitrogen Availability on Dehalococcoides mccartyi Reductive Dechlorination Activity by Devrim Kaya (8039411)

“…In PW4 cultures, the addition of NH₄⁺ increased <i>cis</i>-1,2-dichloroethene (cDCE)-to-ethene dechlorination rates about 5-fold (20.6 ± 1.6 versus 3.8 ± 0.5 μM Cl^– d^‑1), and the total number of <i>Dhc</i> 16S rRNA gene copies were about 43-fold higher in incubations with NH₄⁺ ((1.8 ± 0.9) × 10⁸ mL^–1) compared to incubations without NH₄⁺ ((4.1 ± 0.8) × 10⁷ mL^–1). …”

Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments by Stefania Ferro (76724)

“…The inhibition of tyrosinase (Ty, EC 1.14.18.1) represents an efficient strategy of decreasing melanogenesis and skin hyperpigmentation. …”